Tonix Pharmaceuticals (TNXP) Registration Filing summary

Company overview and business model

• Fully integrated biotech company focused on pain management therapies and vaccines for public health challenges, with a primary focus on central nervous system disorders.

• Lead candidate TNX-102 SL targets fibromyalgia, with a New Drug Application under FDA review and a decision expected by August 15, 2025.

• Additional pipeline includes biologics for organ transplant rejection, autoimmunity, cancer, and vaccines for infectious diseases, including government-funded projects.

• Commercial subsidiary markets migraine treatments Zembrace SymTouch and Tosymra.

Financial performance and metrics

• Audited financials for 2024 and 2023 are incorporated by reference, with a going concern warning from auditors.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes, with specific allocations detailed in future prospectus supplements.